Skip to main content

Cellectis S.A.

corporate_fare Company Profile

Cellectis S.A.

CLLS·NASDAQ·Life Sciences·CIK 0001627281

Cellectis S.A. is a clinical-stage biotechnology company that develops gene-editing products. The company focuses on allogeneic chimeric antigen receptor T-cells (CAR T-cells) for immuno-oncology and gene therapy product candidates for other therapeutic areas. Its product pipeline includes BALLI-01, which is being developed to assess the safety, expansion, persistence, and clinical activities of lasme-cel in patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL). Another product, NatHaLi-01, is designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). Cellectis S.A. also develops ALPHA3, which targets Large B-Cell Lymphoma (LBCL), and TRAVERSE, intended for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). Additionally, the company is developing a product for the treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Cellectis S.A. (NASDAQ:CLLS) is a publicly traded company in the Life Sciences sector. Wiseek monitors CLLS SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Cellectis Reports Strong Phase 1 Data for Lasme-cel (100% ORR) and Promising Eti-cel Results at EHA
  • Cellectis's CAR-T Therapy Lasme-cel Receives FDA RMAT Designation for r/r B-ALL
  • FDA Grants RMAT Designation to Cellectis's Lead CAR-T Therapy lasme-cel for r/r B-ALL
  • Cellectis Seeks Shareholder Approval for Massive Dilutive Capital Raises and ATM Program
  • Cellectis to Present Promising Clinical Data for Lasme-cel and Eti-cel at EHA 2026 Congress

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$72.95M
Net Income
-$67.59M
Diluted EPS
-$0.67
Op. Cash Flow
-$39.4M
Free Cash Flow
-$41.76M
Gross Profit
$72.95M
Operating Income
-$33.08M
Cash & Equivalents
$61.53M
Debt / Equity
0.00×
Net Margin
-92.7%
Shares Outstanding
100.34M sh
Source: 20-F · filed 2026-03-19 · accession 0001193125-26-116428

Insider Transactions

CLLS files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with C →
$3.35 +0.26% today
52-week range · as of 2026-06-11 $1.33 – $5.48
Market cap
$230.74M
Volume
74.7K (1.8× avg)
3-mo avg 40.8K
Live data · 2026-06-12 08:58 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed CLLS - Latest Insights

CLLS
Jun 11, 2026, 7:00 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.18
Real-time Price: $3.35 info
Change: +$0.170 (+5%) info
Market Cap: $230.743M info
CLLS
Jun 09, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.33
Real-time Price: $3.35 info
Change: +$0.020 (+0.60%) info
Market Cap: $230.743M info
CLLS
Jun 09, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.33
Real-time Price: $3.35 info
Change: +$0.020 (+0.60%) info
Market Cap: $230.743M info
CLLS
May 20, 2026, 6:52 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $3.66
Real-time Price: $3.35 info
Change: -$0.310 (-8%) info
Market Cap: $230.743M info
CLLS
May 12, 2026, 9:35 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.89
Real-time Price: $3.35 info
Change: -$0.540 (-14%) info
Market Cap: $230.743M info
CLLS
May 11, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $3.35 info
Change: -$0.630 (-16%) info
Market Cap: $230.743M info
CLLS
May 11, 2026, 4:30 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $3.98
Real-time Price: $3.35 info
Change: -$0.630 (-16%) info
Market Cap: $230.743M info
CLLS
May 11, 2026, 4:30 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $3.35 info
Change: -$0.630 (-16%) info
Market Cap: $230.743M info
CLLS
Apr 27, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.01
Real-time Price: $3.35 info
Change: -$0.660 (-16%) info
Market Cap: $230.743M info
CLLS
Apr 13, 2026, 4:35 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $4.36
Real-time Price: $3.35 info
Change: -$1.01 (-23%) info
Market Cap: $230.743M info
CLLS
Mar 19, 2026, 7:52 PM EDT
Filing Type: 20-F
Importance Score:
7
Price at Filing: $3.55
Real-time Price: $3.35 info
Change: -$0.200 (-6%) info
Market Cap: $230.743M info
CLLS
Mar 19, 2026, 7:21 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $3.54
Real-time Price: $3.35 info
Change: -$0.190 (-5%) info
Market Cap: $230.743M info
CLLS
Jan 08, 2026, 4:35 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $4.48
Real-time Price: $3.35 info
Change: -$1.13 (-25%) info
Market Cap: $230.743M info